US 12,239,684 B2
Modulators of complement activity
Michelle Denise Hoarty, Billerica, MA (US); Ketki Ashok Dhamnaskar, Foster City, CA (US); Daniel Elbaum, Newton, MA (US); Kristopher Josephson, San Carlos, CA (US); Kelley Cronin Larson, Quincy, MA (US); Zhong Ma, Lexington, MA (US); Nathan Ezekiel Nims, Winchester, MA (US); Alonso Ricardo, Winchester, MA (US); Kathleen Seyb, Wakefield, MA (US); Guo-Qing Tang, Acton, MA (US); Douglas A. Treco, Arlington, MA (US); Zhaolin Wang, Wellesley, MA (US); Ping Ye, Lexington, MA (US); Hong Zheng, New York, NY (US); and Sarah Jacqueline Perlmutter, Urbana, IL (US)
Assigned to RA PHARMACEUTICALS, INC., Cambridge, MA (US)
Filed by Ra Pharmaceuticals, Inc., Cambridge, MA (US)
Filed on Jun. 1, 2023, as Appl. No. 18/204,907.
Application 18/204,907 is a continuation of application No. 17/143,232, filed on Jan. 7, 2021, granted, now 11,707,503.
Application 17/143,232 is a continuation of application No. 16/776,551, filed on Jan. 30, 2020, granted, now 10,918,691, issued on Feb. 16, 2021.
Application 16/776,551 is a continuation of application No. 16/393,393, filed on Apr. 24, 2019, granted, now 10,588,936, issued on Mar. 17, 2020.
Application 16/393,393 is a continuation of application No. 15/905,158, filed on Feb. 26, 2018, granted, now 10,328,115, issued on Jun. 25, 2019.
Application 15/905,158 is a continuation of application No. 15/547,085, granted, now 9,937,222, issued on Apr. 10, 2018, previously published as PCT/US2016/015412, filed on Jan. 28, 2016.
Claims priority of provisional application 62/185,298, filed on Jun. 26, 2015.
Claims priority of provisional application 62/108,772, filed on Jan. 28, 2015.
Claims priority of application No. PCT/US2015/035473 (WO), filed on Jun. 12, 2015.
Prior Publication US 2024/0156896 A1, May 16, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/00 (2006.01); A61K 38/10 (2006.01); A61K 39/00 (2006.01); C07K 16/36 (2006.01)
CPC A61K 38/10 (2013.01) [A61K 39/00 (2013.01); C07K 16/36 (2013.01); C07K 2317/76 (2013.01)] 13 Claims
 
1. A method of treating a C5-complement-related disorder in a subject, the method comprising administering a polypeptide of SEQ ID NO: 194 or SEQ ID NO: 184 to the subject, wherein hemolysis in the subject is reduced by at least 50% relative to hemolysis levels previously observed in the subject.